Global Biologics and Biosimilars Market Growth 2023-2029
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
LPI (LP Information)' newest research report, the “Biologics and Biosimilars Industry Forecast” looks at past sales and reviews total world Biologics and Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Biologics and Biosimilars sales for 2023 through 2029. With Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics and Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biologics and Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics and Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics and Biosimilars.
The global Biologics and Biosimilars market size is projected to grow from US$ 189000 million in 2022 to US$ 271130 million in 2029; it is expected to grow at a CAGR of 271130 from 2023 to 2029.
The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Biologics and Biosimilars market?
What factors are driving Biologics and Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biologics and Biosimilars market opportunities vary by end market size?
How does Biologics and Biosimilars break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
LPI (LP Information)' newest research report, the “Biologics and Biosimilars Industry Forecast” looks at past sales and reviews total world Biologics and Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Biologics and Biosimilars sales for 2023 through 2029. With Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics and Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biologics and Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics and Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics and Biosimilars.
The global Biologics and Biosimilars market size is projected to grow from US$ 189000 million in 2022 to US$ 271130 million in 2029; it is expected to grow at a CAGR of 271130 from 2023 to 2029.
The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
What is the 10-year outlook for the global Biologics and Biosimilars market?
What factors are driving Biologics and Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biologics and Biosimilars market opportunities vary by end market size?
How does Biologics and Biosimilars break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biologics and Biosimilars Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Biologics and Biosimilars by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Biologics and Biosimilars by Country/Region, 2018, 2022 & 2029
2.2 Biologics and Biosimilars Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Interferon
2.2.3 Erythropoietin
2.2.4 Insulin
2.2.5 Vaccines
2.2.6 Others
2.3 Biologics and Biosimilars Sales by Type
2.3.1 Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)
2.3.2 Global Biologics and Biosimilars Revenue and Market Share by Type (2018-2023)
2.3.3 Global Biologics and Biosimilars Sale Price by Type (2018-2023)
2.4 Biologics and Biosimilars Segment by Application
2.4.1 Tumor
2.4.2 Diabetes
2.4.3 Cardiovascular
2.4.4 Hemophilia
2.4.5 Others
2.5 Biologics and Biosimilars Sales by Application
2.5.1 Global Biologics and Biosimilars Sale Market Share by Application (2018-2023)
2.5.2 Global Biologics and Biosimilars Revenue and Market Share by Application (2018-2023)
2.5.3 Global Biologics and Biosimilars Sale Price by Application (2018-2023)
3 GLOBAL BIOLOGICS AND BIOSIMILARS BY COMPANY
3.1 Global Biologics and Biosimilars Breakdown Data by Company
3.1.1 Global Biologics and Biosimilars Annual Sales by Company (2018-2023)
3.1.2 Global Biologics and Biosimilars Sales Market Share by Company (2018-2023)
3.2 Global Biologics and Biosimilars Annual Revenue by Company (2018-2023)
3.2.1 Global Biologics and Biosimilars Revenue by Company (2018-2023)
3.2.2 Global Biologics and Biosimilars Revenue Market Share by Company (2018-2023)
3.3 Global Biologics and Biosimilars Sale Price by Company
3.4 Key Manufacturers Biologics and Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biologics and Biosimilars Product Location Distribution
3.4.2 Players Biologics and Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BIOLOGICS AND BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Biologics and Biosimilars Market Size by Geographic Region (2018-2023)
4.1.1 Global Biologics and Biosimilars Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Biologics and Biosimilars Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Biologics and Biosimilars Market Size by Country/Region (2018-2023)
4.2.1 Global Biologics and Biosimilars Annual Sales by Country/Region (2018-2023)
4.2.2 Global Biologics and Biosimilars Annual Revenue by Country/Region (2018-2023)
4.3 Americas Biologics and Biosimilars Sales Growth
4.4 APAC Biologics and Biosimilars Sales Growth
4.5 Europe Biologics and Biosimilars Sales Growth
4.6 Middle East & Africa Biologics and Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Biologics and Biosimilars Sales by Country
5.1.1 Americas Biologics and Biosimilars Sales by Country (2018-2023)
5.1.2 Americas Biologics and Biosimilars Revenue by Country (2018-2023)
5.2 Americas Biologics and Biosimilars Sales by Type
5.3 Americas Biologics and Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics and Biosimilars Sales by Region
6.1.1 APAC Biologics and Biosimilars Sales by Region (2018-2023)
6.1.2 APAC Biologics and Biosimilars Revenue by Region (2018-2023)
6.2 APAC Biologics and Biosimilars Sales by Type
6.3 APAC Biologics and Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biologics and Biosimilars by Country
7.1.1 Europe Biologics and Biosimilars Sales by Country (2018-2023)
7.1.2 Europe Biologics and Biosimilars Revenue by Country (2018-2023)
7.2 Europe Biologics and Biosimilars Sales by Type
7.3 Europe Biologics and Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biologics and Biosimilars by Country
8.1.1 Middle East & Africa Biologics and Biosimilars Sales by Country (2018-2023)
8.1.2 Middle East & Africa Biologics and Biosimilars Revenue by Country (2018-2023)
8.2 Middle East & Africa Biologics and Biosimilars Sales by Type
8.3 Middle East & Africa Biologics and Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biologics and Biosimilars
10.3 Manufacturing Process Analysis of Biologics and Biosimilars
10.4 Industry Chain Structure of Biologics and Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biologics and Biosimilars Distributors
11.3 Biologics and Biosimilars Customer
12 WORLD FORECAST REVIEW FOR BIOLOGICS AND BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Biologics and Biosimilars Market Size Forecast by Region
12.1.1 Global Biologics and Biosimilars Forecast by Region (2024-2029)
12.1.2 Global Biologics and Biosimilars Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Biologics and Biosimilars Forecast by Type
12.7 Global Biologics and Biosimilars Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Biologics and Biosimilars Product Portfolios and Specifications
13.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Biologics and Biosimilars Product Portfolios and Specifications
13.2.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 AbbVie
13.3.1 AbbVie Company Information
13.3.2 AbbVie Biologics and Biosimilars Product Portfolios and Specifications
13.3.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AbbVie Main Business Overview
13.3.5 AbbVie Latest Developments
13.4 Sanofi-Aventis
13.4.1 Sanofi-Aventis Company Information
13.4.2 Sanofi-Aventis Biologics and Biosimilars Product Portfolios and Specifications
13.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Sanofi-Aventis Main Business Overview
13.4.5 Sanofi-Aventis Latest Developments
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Information
13.5.2 Johnson & Johnson Biologics and Biosimilars Product Portfolios and Specifications
13.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Johnson & Johnson Main Business Overview
13.5.5 Johnson & Johnson Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Biologics and Biosimilars Product Portfolios and Specifications
13.6.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Novo Nordisk
13.7.1 Novo Nordisk Company Information
13.7.2 Novo Nordisk Biologics and Biosimilars Product Portfolios and Specifications
13.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Novo Nordisk Main Business Overview
13.7.5 Novo Nordisk Latest Developments
13.8 Eli Lilly
13.8.1 Eli Lilly Company Information
13.8.2 Eli Lilly Biologics and Biosimilars Product Portfolios and Specifications
13.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Eli Lilly Main Business Overview
13.8.5 Eli Lilly Latest Developments
13.9 Novartis
13.9.1 Novartis Company Information
13.9.2 Novartis Biologics and Biosimilars Product Portfolios and Specifications
13.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novartis Main Business Overview
13.9.5 Novartis Latest Developments
13.10 Merck
13.10.1 Merck Company Information
13.10.2 Merck Biologics and Biosimilars Product Portfolios and Specifications
13.10.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Merck Main Business Overview
13.10.5 Merck Latest Developments
13.11 3sbio
13.11.1 3sbio Company Information
13.11.2 3sbio Biologics and Biosimilars Product Portfolios and Specifications
13.11.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 3sbio Main Business Overview
13.11.5 3sbio Latest Developments
13.12 Changchun High Tech
13.12.1 Changchun High Tech Company Information
13.12.2 Changchun High Tech Biologics and Biosimilars Product Portfolios and Specifications
13.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Changchun High Tech Main Business Overview
13.12.5 Changchun High Tech Latest Developments
13.13 CP Guojian
13.13.1 CP Guojian Company Information
13.13.2 CP Guojian Biologics and Biosimilars Product Portfolios and Specifications
13.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 CP Guojian Main Business Overview
13.13.5 CP Guojian Latest Developments
13.14 Biotech
13.14.1 Biotech Company Information
13.14.2 Biotech Biologics and Biosimilars Product Portfolios and Specifications
13.14.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Biotech Main Business Overview
13.14.5 Biotech Latest Developments
13.15 Gelgen
13.15.1 Gelgen Company Information
13.15.2 Gelgen Biologics and Biosimilars Product Portfolios and Specifications
13.15.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Gelgen Main Business Overview
13.15.5 Gelgen Latest Developments
13.16 Innovent
13.16.1 Innovent Company Information
13.16.2 Innovent Biologics and Biosimilars Product Portfolios and Specifications
13.16.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Innovent Main Business Overview
13.16.5 Innovent Latest Developments
13.17 Dong Bao
13.17.1 Dong Bao Company Information
13.17.2 Dong Bao Biologics and Biosimilars Product Portfolios and Specifications
13.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Dong Bao Main Business Overview
13.17.5 Dong Bao Latest Developments
13.18 Ganlee
13.18.1 Ganlee Company Information
13.18.2 Ganlee Biologics and Biosimilars Product Portfolios and Specifications
13.18.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Ganlee Main Business Overview
13.18.5 Ganlee Latest Developments
13.19 United Laboratories
13.19.1 United Laboratories Company Information
13.19.2 United Laboratories Biologics and Biosimilars Product Portfolios and Specifications
13.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 United Laboratories Main Business Overview
13.19.5 United Laboratories Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biologics and Biosimilars Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Biologics and Biosimilars by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Biologics and Biosimilars by Country/Region, 2018, 2022 & 2029
2.2 Biologics and Biosimilars Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Interferon
2.2.3 Erythropoietin
2.2.4 Insulin
2.2.5 Vaccines
2.2.6 Others
2.3 Biologics and Biosimilars Sales by Type
2.3.1 Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)
2.3.2 Global Biologics and Biosimilars Revenue and Market Share by Type (2018-2023)
2.3.3 Global Biologics and Biosimilars Sale Price by Type (2018-2023)
2.4 Biologics and Biosimilars Segment by Application
2.4.1 Tumor
2.4.2 Diabetes
2.4.3 Cardiovascular
2.4.4 Hemophilia
2.4.5 Others
2.5 Biologics and Biosimilars Sales by Application
2.5.1 Global Biologics and Biosimilars Sale Market Share by Application (2018-2023)
2.5.2 Global Biologics and Biosimilars Revenue and Market Share by Application (2018-2023)
2.5.3 Global Biologics and Biosimilars Sale Price by Application (2018-2023)
3 GLOBAL BIOLOGICS AND BIOSIMILARS BY COMPANY
3.1 Global Biologics and Biosimilars Breakdown Data by Company
3.1.1 Global Biologics and Biosimilars Annual Sales by Company (2018-2023)
3.1.2 Global Biologics and Biosimilars Sales Market Share by Company (2018-2023)
3.2 Global Biologics and Biosimilars Annual Revenue by Company (2018-2023)
3.2.1 Global Biologics and Biosimilars Revenue by Company (2018-2023)
3.2.2 Global Biologics and Biosimilars Revenue Market Share by Company (2018-2023)
3.3 Global Biologics and Biosimilars Sale Price by Company
3.4 Key Manufacturers Biologics and Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biologics and Biosimilars Product Location Distribution
3.4.2 Players Biologics and Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BIOLOGICS AND BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Biologics and Biosimilars Market Size by Geographic Region (2018-2023)
4.1.1 Global Biologics and Biosimilars Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Biologics and Biosimilars Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Biologics and Biosimilars Market Size by Country/Region (2018-2023)
4.2.1 Global Biologics and Biosimilars Annual Sales by Country/Region (2018-2023)
4.2.2 Global Biologics and Biosimilars Annual Revenue by Country/Region (2018-2023)
4.3 Americas Biologics and Biosimilars Sales Growth
4.4 APAC Biologics and Biosimilars Sales Growth
4.5 Europe Biologics and Biosimilars Sales Growth
4.6 Middle East & Africa Biologics and Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Biologics and Biosimilars Sales by Country
5.1.1 Americas Biologics and Biosimilars Sales by Country (2018-2023)
5.1.2 Americas Biologics and Biosimilars Revenue by Country (2018-2023)
5.2 Americas Biologics and Biosimilars Sales by Type
5.3 Americas Biologics and Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics and Biosimilars Sales by Region
6.1.1 APAC Biologics and Biosimilars Sales by Region (2018-2023)
6.1.2 APAC Biologics and Biosimilars Revenue by Region (2018-2023)
6.2 APAC Biologics and Biosimilars Sales by Type
6.3 APAC Biologics and Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biologics and Biosimilars by Country
7.1.1 Europe Biologics and Biosimilars Sales by Country (2018-2023)
7.1.2 Europe Biologics and Biosimilars Revenue by Country (2018-2023)
7.2 Europe Biologics and Biosimilars Sales by Type
7.3 Europe Biologics and Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biologics and Biosimilars by Country
8.1.1 Middle East & Africa Biologics and Biosimilars Sales by Country (2018-2023)
8.1.2 Middle East & Africa Biologics and Biosimilars Revenue by Country (2018-2023)
8.2 Middle East & Africa Biologics and Biosimilars Sales by Type
8.3 Middle East & Africa Biologics and Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biologics and Biosimilars
10.3 Manufacturing Process Analysis of Biologics and Biosimilars
10.4 Industry Chain Structure of Biologics and Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biologics and Biosimilars Distributors
11.3 Biologics and Biosimilars Customer
12 WORLD FORECAST REVIEW FOR BIOLOGICS AND BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Biologics and Biosimilars Market Size Forecast by Region
12.1.1 Global Biologics and Biosimilars Forecast by Region (2024-2029)
12.1.2 Global Biologics and Biosimilars Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Biologics and Biosimilars Forecast by Type
12.7 Global Biologics and Biosimilars Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Biologics and Biosimilars Product Portfolios and Specifications
13.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Biologics and Biosimilars Product Portfolios and Specifications
13.2.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 AbbVie
13.3.1 AbbVie Company Information
13.3.2 AbbVie Biologics and Biosimilars Product Portfolios and Specifications
13.3.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AbbVie Main Business Overview
13.3.5 AbbVie Latest Developments
13.4 Sanofi-Aventis
13.4.1 Sanofi-Aventis Company Information
13.4.2 Sanofi-Aventis Biologics and Biosimilars Product Portfolios and Specifications
13.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Sanofi-Aventis Main Business Overview
13.4.5 Sanofi-Aventis Latest Developments
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Information
13.5.2 Johnson & Johnson Biologics and Biosimilars Product Portfolios and Specifications
13.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Johnson & Johnson Main Business Overview
13.5.5 Johnson & Johnson Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Biologics and Biosimilars Product Portfolios and Specifications
13.6.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Novo Nordisk
13.7.1 Novo Nordisk Company Information
13.7.2 Novo Nordisk Biologics and Biosimilars Product Portfolios and Specifications
13.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Novo Nordisk Main Business Overview
13.7.5 Novo Nordisk Latest Developments
13.8 Eli Lilly
13.8.1 Eli Lilly Company Information
13.8.2 Eli Lilly Biologics and Biosimilars Product Portfolios and Specifications
13.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Eli Lilly Main Business Overview
13.8.5 Eli Lilly Latest Developments
13.9 Novartis
13.9.1 Novartis Company Information
13.9.2 Novartis Biologics and Biosimilars Product Portfolios and Specifications
13.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novartis Main Business Overview
13.9.5 Novartis Latest Developments
13.10 Merck
13.10.1 Merck Company Information
13.10.2 Merck Biologics and Biosimilars Product Portfolios and Specifications
13.10.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Merck Main Business Overview
13.10.5 Merck Latest Developments
13.11 3sbio
13.11.1 3sbio Company Information
13.11.2 3sbio Biologics and Biosimilars Product Portfolios and Specifications
13.11.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 3sbio Main Business Overview
13.11.5 3sbio Latest Developments
13.12 Changchun High Tech
13.12.1 Changchun High Tech Company Information
13.12.2 Changchun High Tech Biologics and Biosimilars Product Portfolios and Specifications
13.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Changchun High Tech Main Business Overview
13.12.5 Changchun High Tech Latest Developments
13.13 CP Guojian
13.13.1 CP Guojian Company Information
13.13.2 CP Guojian Biologics and Biosimilars Product Portfolios and Specifications
13.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 CP Guojian Main Business Overview
13.13.5 CP Guojian Latest Developments
13.14 Biotech
13.14.1 Biotech Company Information
13.14.2 Biotech Biologics and Biosimilars Product Portfolios and Specifications
13.14.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Biotech Main Business Overview
13.14.5 Biotech Latest Developments
13.15 Gelgen
13.15.1 Gelgen Company Information
13.15.2 Gelgen Biologics and Biosimilars Product Portfolios and Specifications
13.15.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Gelgen Main Business Overview
13.15.5 Gelgen Latest Developments
13.16 Innovent
13.16.1 Innovent Company Information
13.16.2 Innovent Biologics and Biosimilars Product Portfolios and Specifications
13.16.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Innovent Main Business Overview
13.16.5 Innovent Latest Developments
13.17 Dong Bao
13.17.1 Dong Bao Company Information
13.17.2 Dong Bao Biologics and Biosimilars Product Portfolios and Specifications
13.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Dong Bao Main Business Overview
13.17.5 Dong Bao Latest Developments
13.18 Ganlee
13.18.1 Ganlee Company Information
13.18.2 Ganlee Biologics and Biosimilars Product Portfolios and Specifications
13.18.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Ganlee Main Business Overview
13.18.5 Ganlee Latest Developments
13.19 United Laboratories
13.19.1 United Laboratories Company Information
13.19.2 United Laboratories Biologics and Biosimilars Product Portfolios and Specifications
13.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 United Laboratories Main Business Overview
13.19.5 United Laboratories Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Biologics and Biosimilars Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Biologics and Biosimilars Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Interferon
Table 5. Major Players of Erythropoietin
Table 6. Major Players of Insulin
Table 7. Major Players of Vaccines
Table 8. Major Players of Others
Table 9. Global Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 10. Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Table 11. Global Biologics and Biosimilars Revenue by Type (2018-2023) & ($ million)
Table 12. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)
Table 13. Global Biologics and Biosimilars Sale Price by Type (2018-2023) & (USD/Unit)
Table 14. Global Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 15. Global Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Table 16. Global Biologics and Biosimilars Revenue by Application (2018-2023)
Table 17. Global Biologics and Biosimilars Revenue Market Share by Application (2018-2023)
Table 18. Global Biologics and Biosimilars Sale Price by Application (2018-2023) & (USD/Unit)
Table 19. Global Biologics and Biosimilars Sales by Company (2018-2023) & (K Units)
Table 20. Global Biologics and Biosimilars Sales Market Share by Company (2018-2023)
Table 21. Global Biologics and Biosimilars Revenue by Company (2018-2023) ($ Millions)
Table 22. Global Biologics and Biosimilars Revenue Market Share by Company (2018-2023)
Table 23. Global Biologics and Biosimilars Sale Price by Company (2018-2023) & (USD/Unit)
Table 24. Key Manufacturers Biologics and Biosimilars Producing Area Distribution and Sales Area
Table 25. Players Biologics and Biosimilars Products Offered
Table 26. Biologics and Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Biologics and Biosimilars Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global Biologics and Biosimilars Sales Market Share Geographic Region (2018-2023)
Table 31. Global Biologics and Biosimilars Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global Biologics and Biosimilars Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global Biologics and Biosimilars Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global Biologics and Biosimilars Sales Market Share by Country/Region (2018-2023)
Table 35. Global Biologics and Biosimilars Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global Biologics and Biosimilars Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 38. Americas Biologics and Biosimilars Sales Market Share by Country (2018-2023)
Table 39. Americas Biologics and Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas Biologics and Biosimilars Revenue Market Share by Country (2018-2023)
Table 41. Americas Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 42. Americas Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 43. APAC Biologics and Biosimilars Sales by Region (2018-2023) & (K Units)
Table 44. APAC Biologics and Biosimilars Sales Market Share by Region (2018-2023)
Table 45. APAC Biologics and Biosimilars Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC Biologics and Biosimilars Revenue Market Share by Region (2018-2023)
Table 47. APAC Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 48. APAC Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 49. Europe Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 50. Europe Biologics and Biosimilars Sales Market Share by Country (2018-2023)
Table 51. Europe Biologics and Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe Biologics and Biosimilars Revenue Market Share by Country (2018-2023)
Table 53. Europe Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 54. Europe Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa Biologics and Biosimilars Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa Biologics and Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa Biologics and Biosimilars Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Biologics and Biosimilars
Table 62. Key Market Challenges & Risks of Biologics and Biosimilars
Table 63. Key Industry Trends of Biologics and Biosimilars
Table 64. Biologics and Biosimilars Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Biologics and Biosimilars Distributors List
Table 67. Biologics and Biosimilars Customer List
Table 68. Global Biologics and Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global Biologics and Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC Biologics and Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC Biologics and Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global Biologics and Biosimilars Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global Biologics and Biosimilars Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global Biologics and Biosimilars Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global Biologics and Biosimilars Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. Roche Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 83. Roche Biologics and Biosimilars Product Portfolios and Specifications
Table 84. Roche Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 85. Roche Main Business
Table 86. Roche Latest Developments
Table 87. Amgen Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 88. Amgen Biologics and Biosimilars Product Portfolios and Specifications
Table 89. Amgen Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 90. Amgen Main Business
Table 91. Amgen Latest Developments
Table 92. AbbVie Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 93. AbbVie Biologics and Biosimilars Product Portfolios and Specifications
Table 94. AbbVie Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 95. AbbVie Main Business
Table 96. AbbVie Latest Developments
Table 97. Sanofi-Aventis Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 98. Sanofi-Aventis Biologics and Biosimilars Product Portfolios and Specifications
Table 99. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 100. Sanofi-Aventis Main Business
Table 101. Sanofi-Aventis Latest Developments
Table 102. Johnson & Johnson Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 103. Johnson & Johnson Biologics and Biosimilars Product Portfolios and Specifications
Table 104. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 105. Johnson & Johnson Main Business
Table 106. Johnson & Johnson Latest Developments
Table 107. Pfizer Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Pfizer Biologics and Biosimilars Product Portfolios and Specifications
Table 109. Pfizer Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 110. Pfizer Main Business
Table 111. Pfizer Latest Developments
Table 112. Novo Nordisk Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 113. Novo Nordisk Biologics and Biosimilars Product Portfolios and Specifications
Table 114. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 115. Novo Nordisk Main Business
Table 116. Novo Nordisk Latest Developments
Table 117. Eli Lilly Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 118. Eli Lilly Biologics and Biosimilars Product Portfolios and Specifications
Table 119. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 120. Eli Lilly Main Business
Table 121. Eli Lilly Latest Developments
Table 122. Novartis Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 123. Novartis Biologics and Biosimilars Product Portfolios and Specifications
Table 124. Novartis Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 125. Novartis Main Business
Table 126. Novartis Latest Developments
Table 127. Merck Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 128. Merck Biologics and Biosimilars Product Portfolios and Specifications
Table 129. Merck Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 130. Merck Main Business
Table 131. Merck Latest Developments
Table 132. 3sbio Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 133. 3sbio Biologics and Biosimilars Product Portfolios and Specifications
Table 134. 3sbio Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 135. 3sbio Main Business
Table 136. 3sbio Latest Developments
Table 137. Changchun High Tech Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 138. Changchun High Tech Biologics and Biosimilars Product Portfolios and Specifications
Table 139. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 140. Changchun High Tech Main Business
Table 141. Changchun High Tech Latest Developments
Table 142. CP Guojian Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 143. CP Guojian Biologics and Biosimilars Product Portfolios and Specifications
Table 144. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 145. CP Guojian Main Business
Table 146. CP Guojian Latest Developments
Table 147. Biotech Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 148. Biotech Biologics and Biosimilars Product Portfolios and Specifications
Table 149. Biotech Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 150. Biotech Main Business
Table 151. Biotech Latest Developments
Table 152. Gelgen Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 153. Gelgen Biologics and Biosimilars Product Portfolios and Specifications
Table 154. Gelgen Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 155. Gelgen Main Business
Table 156. Gelgen Latest Developments
Table 157. Innovent Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 158. Innovent Biologics and Biosimilars Product Portfolios and Specifications
Table 159. Innovent Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 160. Innovent Main Business
Table 161. Innovent Latest Developments
Table 162. Dong Bao Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 163. Dong Bao Biologics and Biosimilars Product Portfolios and Specifications
Table 164. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 165. Dong Bao Main Business
Table 166. Dong Bao Latest Developments
Table 167. Ganlee Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 168. Ganlee Biologics and Biosimilars Product Portfolios and Specifications
Table 169. Ganlee Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 170. Ganlee Main Business
Table 171. Ganlee Latest Developments
Table 172. United Laboratories Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 173. United Laboratories Biologics and Biosimilars Product Portfolios and Specifications
Table 174. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 175. United Laboratories Main Business
Table 176. United Laboratories Latest Developments
Table 1. Biologics and Biosimilars Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Biologics and Biosimilars Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Interferon
Table 5. Major Players of Erythropoietin
Table 6. Major Players of Insulin
Table 7. Major Players of Vaccines
Table 8. Major Players of Others
Table 9. Global Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 10. Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Table 11. Global Biologics and Biosimilars Revenue by Type (2018-2023) & ($ million)
Table 12. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)
Table 13. Global Biologics and Biosimilars Sale Price by Type (2018-2023) & (USD/Unit)
Table 14. Global Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 15. Global Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Table 16. Global Biologics and Biosimilars Revenue by Application (2018-2023)
Table 17. Global Biologics and Biosimilars Revenue Market Share by Application (2018-2023)
Table 18. Global Biologics and Biosimilars Sale Price by Application (2018-2023) & (USD/Unit)
Table 19. Global Biologics and Biosimilars Sales by Company (2018-2023) & (K Units)
Table 20. Global Biologics and Biosimilars Sales Market Share by Company (2018-2023)
Table 21. Global Biologics and Biosimilars Revenue by Company (2018-2023) ($ Millions)
Table 22. Global Biologics and Biosimilars Revenue Market Share by Company (2018-2023)
Table 23. Global Biologics and Biosimilars Sale Price by Company (2018-2023) & (USD/Unit)
Table 24. Key Manufacturers Biologics and Biosimilars Producing Area Distribution and Sales Area
Table 25. Players Biologics and Biosimilars Products Offered
Table 26. Biologics and Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Biologics and Biosimilars Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global Biologics and Biosimilars Sales Market Share Geographic Region (2018-2023)
Table 31. Global Biologics and Biosimilars Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global Biologics and Biosimilars Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global Biologics and Biosimilars Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global Biologics and Biosimilars Sales Market Share by Country/Region (2018-2023)
Table 35. Global Biologics and Biosimilars Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global Biologics and Biosimilars Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 38. Americas Biologics and Biosimilars Sales Market Share by Country (2018-2023)
Table 39. Americas Biologics and Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas Biologics and Biosimilars Revenue Market Share by Country (2018-2023)
Table 41. Americas Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 42. Americas Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 43. APAC Biologics and Biosimilars Sales by Region (2018-2023) & (K Units)
Table 44. APAC Biologics and Biosimilars Sales Market Share by Region (2018-2023)
Table 45. APAC Biologics and Biosimilars Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC Biologics and Biosimilars Revenue Market Share by Region (2018-2023)
Table 47. APAC Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 48. APAC Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 49. Europe Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 50. Europe Biologics and Biosimilars Sales Market Share by Country (2018-2023)
Table 51. Europe Biologics and Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe Biologics and Biosimilars Revenue Market Share by Country (2018-2023)
Table 53. Europe Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 54. Europe Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa Biologics and Biosimilars Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa Biologics and Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa Biologics and Biosimilars Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Biologics and Biosimilars
Table 62. Key Market Challenges & Risks of Biologics and Biosimilars
Table 63. Key Industry Trends of Biologics and Biosimilars
Table 64. Biologics and Biosimilars Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Biologics and Biosimilars Distributors List
Table 67. Biologics and Biosimilars Customer List
Table 68. Global Biologics and Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global Biologics and Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC Biologics and Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC Biologics and Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa Biologics and Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa Biologics and Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global Biologics and Biosimilars Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global Biologics and Biosimilars Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global Biologics and Biosimilars Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global Biologics and Biosimilars Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. Roche Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 83. Roche Biologics and Biosimilars Product Portfolios and Specifications
Table 84. Roche Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 85. Roche Main Business
Table 86. Roche Latest Developments
Table 87. Amgen Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 88. Amgen Biologics and Biosimilars Product Portfolios and Specifications
Table 89. Amgen Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 90. Amgen Main Business
Table 91. Amgen Latest Developments
Table 92. AbbVie Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 93. AbbVie Biologics and Biosimilars Product Portfolios and Specifications
Table 94. AbbVie Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 95. AbbVie Main Business
Table 96. AbbVie Latest Developments
Table 97. Sanofi-Aventis Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 98. Sanofi-Aventis Biologics and Biosimilars Product Portfolios and Specifications
Table 99. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 100. Sanofi-Aventis Main Business
Table 101. Sanofi-Aventis Latest Developments
Table 102. Johnson & Johnson Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 103. Johnson & Johnson Biologics and Biosimilars Product Portfolios and Specifications
Table 104. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 105. Johnson & Johnson Main Business
Table 106. Johnson & Johnson Latest Developments
Table 107. Pfizer Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Pfizer Biologics and Biosimilars Product Portfolios and Specifications
Table 109. Pfizer Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 110. Pfizer Main Business
Table 111. Pfizer Latest Developments
Table 112. Novo Nordisk Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 113. Novo Nordisk Biologics and Biosimilars Product Portfolios and Specifications
Table 114. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 115. Novo Nordisk Main Business
Table 116. Novo Nordisk Latest Developments
Table 117. Eli Lilly Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 118. Eli Lilly Biologics and Biosimilars Product Portfolios and Specifications
Table 119. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 120. Eli Lilly Main Business
Table 121. Eli Lilly Latest Developments
Table 122. Novartis Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 123. Novartis Biologics and Biosimilars Product Portfolios and Specifications
Table 124. Novartis Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 125. Novartis Main Business
Table 126. Novartis Latest Developments
Table 127. Merck Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 128. Merck Biologics and Biosimilars Product Portfolios and Specifications
Table 129. Merck Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 130. Merck Main Business
Table 131. Merck Latest Developments
Table 132. 3sbio Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 133. 3sbio Biologics and Biosimilars Product Portfolios and Specifications
Table 134. 3sbio Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 135. 3sbio Main Business
Table 136. 3sbio Latest Developments
Table 137. Changchun High Tech Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 138. Changchun High Tech Biologics and Biosimilars Product Portfolios and Specifications
Table 139. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 140. Changchun High Tech Main Business
Table 141. Changchun High Tech Latest Developments
Table 142. CP Guojian Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 143. CP Guojian Biologics and Biosimilars Product Portfolios and Specifications
Table 144. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 145. CP Guojian Main Business
Table 146. CP Guojian Latest Developments
Table 147. Biotech Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 148. Biotech Biologics and Biosimilars Product Portfolios and Specifications
Table 149. Biotech Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 150. Biotech Main Business
Table 151. Biotech Latest Developments
Table 152. Gelgen Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 153. Gelgen Biologics and Biosimilars Product Portfolios and Specifications
Table 154. Gelgen Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 155. Gelgen Main Business
Table 156. Gelgen Latest Developments
Table 157. Innovent Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 158. Innovent Biologics and Biosimilars Product Portfolios and Specifications
Table 159. Innovent Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 160. Innovent Main Business
Table 161. Innovent Latest Developments
Table 162. Dong Bao Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 163. Dong Bao Biologics and Biosimilars Product Portfolios and Specifications
Table 164. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 165. Dong Bao Main Business
Table 166. Dong Bao Latest Developments
Table 167. Ganlee Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 168. Ganlee Biologics and Biosimilars Product Portfolios and Specifications
Table 169. Ganlee Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 170. Ganlee Main Business
Table 171. Ganlee Latest Developments
Table 172. United Laboratories Basic Information, Biologics and Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 173. United Laboratories Biologics and Biosimilars Product Portfolios and Specifications
Table 174. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 175. United Laboratories Main Business
Table 176. United Laboratories Latest Developments
LIST OF FIGURES
Figure 1. Picture of Biologics and Biosimilars
Figure 2. Biologics and Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biologics and Biosimilars Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Biologics and Biosimilars Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Biologics and Biosimilars Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Monoclonal Antibodies
Figure 10. Product Picture of Interferon
Figure 11. Product Picture of Erythropoietin
Figure 12. Product Picture of Insulin
Figure 13. Product Picture of Vaccines
Figure 14. Product Picture of Others
Figure 15. Global Biologics and Biosimilars Sales Market Share by Type in 2022
Figure 16. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)
Figure 17. Biologics and Biosimilars Consumed in Tumor
Figure 18. Global Biologics and Biosimilars Market: Tumor (2018-2023) & (K Units)
Figure 19. Biologics and Biosimilars Consumed in Diabetes
Figure 20. Global Biologics and Biosimilars Market: Diabetes (2018-2023) & (K Units)
Figure 21. Biologics and Biosimilars Consumed in Cardiovascular
Figure 22. Global Biologics and Biosimilars Market: Cardiovascular (2018-2023) & (K Units)
Figure 23. Biologics and Biosimilars Consumed in Hemophilia
Figure 24. Global Biologics and Biosimilars Market: Hemophilia (2018-2023) & (K Units)
Figure 25. Biologics and Biosimilars Consumed in Others
Figure 26. Global Biologics and Biosimilars Market: Others (2018-2023) & (K Units)
Figure 27. Global Biologics and Biosimilars Sales Market Share by Application (2022)
Figure 28. Global Biologics and Biosimilars Revenue Market Share by Application in 2022
Figure 29. Biologics and Biosimilars Sales Market by Company in 2022 (K Units)
Figure 30. Global Biologics and Biosimilars Sales Market Share by Company in 2022
Figure 31. Biologics and Biosimilars Revenue Market by Company in 2022 ($ Million)
Figure 32. Global Biologics and Biosimilars Revenue Market Share by Company in 2022
Figure 33. Global Biologics and Biosimilars Sales Market Share by Geographic Region (2018-2023)
Figure 34. Global Biologics and Biosimilars Revenue Market Share by Geographic Region in 2022
Figure 35. Americas Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 36. Americas Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 37. APAC Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 38. APAC Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 39. Europe Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 40. Europe Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 41. Middle East & Africa Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 42. Middle East & Africa Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 43. Americas Biologics and Biosimilars Sales Market Share by Country in 2022
Figure 44. Americas Biologics and Biosimilars Revenue Market Share by Country in 2022
Figure 45. Americas Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 46. Americas Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 47. United States Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 48. Canada Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 49. Mexico Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 50. Brazil Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 51. APAC Biologics and Biosimilars Sales Market Share by Region in 2022
Figure 52. APAC Biologics and Biosimilars Revenue Market Share by Regions in 2022
Figure 53. APAC Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 54. APAC Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 55. China Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 56. Japan Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 57. South Korea Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 58. Southeast Asia Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 59. India Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 60. Australia Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 61. China Taiwan Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 62. Europe Biologics and Biosimilars Sales Market Share by Country in 2022
Figure 63. Europe Biologics and Biosimilars Revenue Market Share by Country in 2022
Figure 64. Europe Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 65. Europe Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 66. Germany Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 67. France Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 68. UK Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 69. Italy Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 70. Russia Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 71. Middle East & Africa Biologics and Biosimilars Sales Market Share by Country in 2022
Figure 72. Middle East & Africa Biologics and Biosimilars Revenue Market Share by Country in 2022
Figure 73. Middle East & Africa Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 74. Middle East & Africa Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 75. Egypt Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 76. South Africa Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 77. Israel Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 78. Turkey Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 79. GCC Country Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Biologics and Biosimilars in 2022
Figure 81. Manufacturing Process Analysis of Biologics and Biosimilars
Figure 82. Industry Chain Structure of Biologics and Biosimilars
Figure 83. Channels of Distribution
Figure 84. Global Biologics and Biosimilars Sales Market Forecast by Region (2024-2029)
Figure 85. Global Biologics and Biosimilars Revenue Market Share Forecast by Region (2024-2029)
Figure 86. Global Biologics and Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 87. Global Biologics and Biosimilars Revenue Market Share Forecast by Type (2024-2029)
Figure 88. Global Biologics and Biosimilars Sales Market Share Forecast by Application (2024-2029)
Figure 89. Global Biologics and Biosimilars Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Biologics and Biosimilars
Figure 2. Biologics and Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biologics and Biosimilars Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Biologics and Biosimilars Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Biologics and Biosimilars Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Monoclonal Antibodies
Figure 10. Product Picture of Interferon
Figure 11. Product Picture of Erythropoietin
Figure 12. Product Picture of Insulin
Figure 13. Product Picture of Vaccines
Figure 14. Product Picture of Others
Figure 15. Global Biologics and Biosimilars Sales Market Share by Type in 2022
Figure 16. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)
Figure 17. Biologics and Biosimilars Consumed in Tumor
Figure 18. Global Biologics and Biosimilars Market: Tumor (2018-2023) & (K Units)
Figure 19. Biologics and Biosimilars Consumed in Diabetes
Figure 20. Global Biologics and Biosimilars Market: Diabetes (2018-2023) & (K Units)
Figure 21. Biologics and Biosimilars Consumed in Cardiovascular
Figure 22. Global Biologics and Biosimilars Market: Cardiovascular (2018-2023) & (K Units)
Figure 23. Biologics and Biosimilars Consumed in Hemophilia
Figure 24. Global Biologics and Biosimilars Market: Hemophilia (2018-2023) & (K Units)
Figure 25. Biologics and Biosimilars Consumed in Others
Figure 26. Global Biologics and Biosimilars Market: Others (2018-2023) & (K Units)
Figure 27. Global Biologics and Biosimilars Sales Market Share by Application (2022)
Figure 28. Global Biologics and Biosimilars Revenue Market Share by Application in 2022
Figure 29. Biologics and Biosimilars Sales Market by Company in 2022 (K Units)
Figure 30. Global Biologics and Biosimilars Sales Market Share by Company in 2022
Figure 31. Biologics and Biosimilars Revenue Market by Company in 2022 ($ Million)
Figure 32. Global Biologics and Biosimilars Revenue Market Share by Company in 2022
Figure 33. Global Biologics and Biosimilars Sales Market Share by Geographic Region (2018-2023)
Figure 34. Global Biologics and Biosimilars Revenue Market Share by Geographic Region in 2022
Figure 35. Americas Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 36. Americas Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 37. APAC Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 38. APAC Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 39. Europe Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 40. Europe Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 41. Middle East & Africa Biologics and Biosimilars Sales 2018-2023 (K Units)
Figure 42. Middle East & Africa Biologics and Biosimilars Revenue 2018-2023 ($ Millions)
Figure 43. Americas Biologics and Biosimilars Sales Market Share by Country in 2022
Figure 44. Americas Biologics and Biosimilars Revenue Market Share by Country in 2022
Figure 45. Americas Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 46. Americas Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 47. United States Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 48. Canada Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 49. Mexico Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 50. Brazil Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 51. APAC Biologics and Biosimilars Sales Market Share by Region in 2022
Figure 52. APAC Biologics and Biosimilars Revenue Market Share by Regions in 2022
Figure 53. APAC Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 54. APAC Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 55. China Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 56. Japan Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 57. South Korea Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 58. Southeast Asia Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 59. India Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 60. Australia Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 61. China Taiwan Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 62. Europe Biologics and Biosimilars Sales Market Share by Country in 2022
Figure 63. Europe Biologics and Biosimilars Revenue Market Share by Country in 2022
Figure 64. Europe Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 65. Europe Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 66. Germany Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 67. France Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 68. UK Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 69. Italy Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 70. Russia Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 71. Middle East & Africa Biologics and Biosimilars Sales Market Share by Country in 2022
Figure 72. Middle East & Africa Biologics and Biosimilars Revenue Market Share by Country in 2022
Figure 73. Middle East & Africa Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Figure 74. Middle East & Africa Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Figure 75. Egypt Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 76. South Africa Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 77. Israel Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 78. Turkey Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 79. GCC Country Biologics and Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Biologics and Biosimilars in 2022
Figure 81. Manufacturing Process Analysis of Biologics and Biosimilars
Figure 82. Industry Chain Structure of Biologics and Biosimilars
Figure 83. Channels of Distribution
Figure 84. Global Biologics and Biosimilars Sales Market Forecast by Region (2024-2029)
Figure 85. Global Biologics and Biosimilars Revenue Market Share Forecast by Region (2024-2029)
Figure 86. Global Biologics and Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 87. Global Biologics and Biosimilars Revenue Market Share Forecast by Type (2024-2029)
Figure 88. Global Biologics and Biosimilars Sales Market Share Forecast by Application (2024-2029)
Figure 89. Global Biologics and Biosimilars Revenue Market Share Forecast by Application (2024-2029)
